BioSpace News Archive

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that three abstracts with data on PEPAXTO ® (melphalan flufenamide, also known as melflufen) in relapsed refractory multiple myeloma,

- AnHeart Therapeutics Co., Ltd . (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually

Transcenta Holding Limited (“Transcenta”), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts reporting on two clinical studies evaluating the company’s drug candidate, alrizomadlin (APG-115),

On May 18, Kintor Pharmaceutical Limited announced that the U.S. Food and Drug Administration has greenlighted proxalutamide’s phase III clinical trial of hospitalised COVID-19 patients to be conducted, which will recruit both male and female patients.

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2021 on Tuesday, May 25, 2021.

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its participation at upcoming virtual investor conferences in June 2021.

VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced the launch of VIAGENEX™

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, announced its participation in two upcoming virtual investor conferences.

Ziopharm Oncology, Inc., held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team.